Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
暂无分享,去创建一个
H. Gold | J. Fallon | J. Guerrero | T. Yasuda | T. Saito | M. Kanke | D. Collen | A. A. Ziskind
[1] H. Gold,et al. Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator. , 1988, Thrombosis research.
[2] H. Gold,et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. , 1988, The Journal of clinical investigation.
[3] D. Collen. Synergism of thrombolytic agents: investigational procedures and clinical potential. , 1988, Circulation.
[4] H. Gold,et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. , 1988, Circulation.
[5] A. Ross,et al. Reinfarction, recurrent angina, and reocclusion after thrombolytic therapy. , 1987, Circulation.
[6] G. Steinbeck,et al. Frequency analysis of the surface electrocardiogram for recognition of acute rejection after orthotopic cardiac transplantation in man. , 1987, Circulation.
[7] B. Sobel,et al. Tissue Plasminogen Activator in Thrombolytic Therapy , 1987 .
[8] I. Jang,et al. Thrombolysis with Recombinant Human Single-Chain Urokinase-Type Plasminogen Activator (rscu-PA): Dose–Response in Dogs with Coronary Artery Thrombosis , 1987, Journal of cardiovascular pharmacology.
[9] V. Darras,et al. Measurement of Urokinase-Type Plasminogen Activator (u-PA) with an Enzyme-Linked Immunosorbent Assay (ELISA) Based on Three Murine Monoclonal Antibodies , 1986, Thrombosis and Haemostasis.
[10] F. Werf,et al. Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents. , 1986, American heart journal.
[11] F. Van de Werf,et al. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. , 1986, Circulation.
[12] M. Verstraete,et al. Synergism of thrombolytic agents in vivo. , 1986, Circulation.
[13] H. Lijnen,et al. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. , 1986, Circulation.
[14] I. Palacios,et al. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. , 1986, Circulation.
[15] J. J. Spadaro,et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator. , 1984, Circulation.
[16] M C Berenbaum,et al. Synergy, additivism and antagonism in immunosuppression. A critical review. , 1977, Clinical and experimental immunology.
[17] M. Verstraete,et al. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). , 1963, Clinica chimica acta; international journal of clinical chemistry.
[18] A. Clauss,et al. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .
[19] D. Ph.DCollenM.. Report of the Meeting of the Subcommittee on Fibrinolysis, San Diego, CA, USA, July 13, 1985 , 1985 .